DK1461300T3 - Antistoffer mod kemotaktiske monocytproteiner - Google Patents

Antistoffer mod kemotaktiske monocytproteiner

Info

Publication number: DK1461300T3
Authority: DK; Denmark
Prior art keywords: antibodies; monocyte proteins; chemotactic; chemotactic monocyte; proteins
Prior art date: 2001-11-30

Application number

DK02792310.1T

Other languages

English (en)

Inventor

Fougerolles Antonin R De

Victor E Kotelianski

Ellen Garber

Carl Reid

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-30

Filing date

2002-11-27

Publication date

2011-10-24

2002-11-27 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2011-10-24 Application granted granted Critical

2011-10-24 Publication of DK1461300T3 publication Critical patent/DK1461300T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK02792310.1T 2001-11-30 2002-11-27 Antistoffer mod kemotaktiske monocytproteiner DK1461300T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US34339101P	2001-11-30	2001-11-30
US38327702P	2002-05-24	2002-05-24
US40046902P	2002-08-01	2002-08-01
PCT/US2002/038229 WO2003048083A2 (en)	2001-11-30	2002-11-27	Antibodies against monocyte chemotactic proteins

Publications (1)

Publication Number	Publication Date
DK1461300T3 true DK1461300T3 (da)	2011-10-24

Family

ID=27407563

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02792310.1T DK1461300T3 (da)	2001-11-30	2002-11-27	Antistoffer mod kemotaktiske monocytproteiner

Country Status (8)

Country	Link
US (6)	US7405277B2 (da)
EP (3)	EP1461300B1 (da)
AR (1)	AR037456A1 (da)
AT (1)	ATE517855T1 (da)
AU (1)	AU2002357770B2 (da)
CA (1)	CA2468733C (da)
DK (1)	DK1461300T3 (da)
WO (1)	WO2003048083A2 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1461300B1 (en)	2001-11-30	2011-07-27	Biogen Idec MA Inc.	Antibodies against monocyte chemotactic proteins
WO2004016767A2 (en) *	2002-08-19	2004-02-26	The President And Fellows Of Harvard College	Evolving new molecular function
GB0228832D0 (en)	2002-12-10	2003-01-15	Novartis Ag	Organic compound
US7964194B2 (en) *	2002-11-15	2011-06-21	Morehouse School Of Medicine	Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
CA2507080C (en)	2002-11-27	2015-01-06	Biogen Idec Ma Inc.	Humanized antibodies against monocyte chemotactic proteins
GB0321997D0 (en) *	2003-09-19	2003-10-22	Novartis Ag	Organic compound
EP1684703A4 (en) *	2003-11-05	2008-10-01	Centocor Inc	METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH MCP-1
DE602005017370D1 (de) *	2004-03-22	2009-12-10	Nuevolution As	Ligationscodierung unter verwendung von oligonukleotidbausteinen
CA2566445C (en)	2004-05-12	2016-02-02	The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services	Methods related to the treatment of neurodegenerative and inflammatory conditions
AU2011265315B2 (en) *	2004-05-12	2014-08-28	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods related to the treatment of neurodegenerative and inflammatory conditions
CA2572289A1 (en) *	2004-06-30	2006-08-17	Centocor, Inc.	Anti-mcp-1 antibodies, compositions, methods and uses
US8114964B2 (en)	2005-05-19	2012-02-14	Centocor, Inc.	Anti-MCP-1 antibodies, compositions, methods and uses
PA8675801A1 (es) *	2005-05-19	2006-12-07	Centocor Inc	Anticuerpos anti-mcp-1, composiciones, metodos y usos
US20070099239A1 (en) *	2005-06-24	2007-05-03	Raymond Tabibiazar	Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
WO2007142241A1 (ja) *	2006-06-05	2007-12-13	Hiroshima University	抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
US20080076120A1 (en) *	2006-09-14	2008-03-27	Millennium Pharmaceuticals, Inc.	Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US7608693B2 (en)	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
WO2008054606A2 (en) *	2006-10-02	2008-05-08	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human il-4 receptor
WO2009001545A1 (ja)	2007-06-22	2008-12-31	Sapporo Medical University	移植片対宿主疾患の検査および治療方法
NZ591471A (en)	2008-08-18	2012-08-31	Pfizer	Antibodies to ccr2
WO2011060076A1 (en) *	2009-11-10	2011-05-19	Amgen Inc.	Anti-c-mpl antibodies
JP5786020B2 (ja) *	2010-04-16	2015-09-30	アボットジャパン株式会社	関節リウマチを診断する方法および試薬
GB201205739D0 (en) *	2012-03-30	2012-05-16	Ucl Business Plc	Treatment of acute inflammation in the respiratory tract
IN2014DN09951A (da) *	2012-05-22	2015-08-14	Shire Human Genetic Therapies
HUE064945T2 (hu)	2012-08-21	2024-04-28	Sanofi Biotechnology	Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával
AU2014268316B2 (en) *	2013-05-23	2019-10-10	Takeda Pharmaceutical Company Limited	Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
TWI633891B (zh)	2013-06-04	2018-09-01	再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI682781B (zh)	2013-07-11	2020-01-21	美商再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2704999C2 (ru)	2014-02-28	2019-11-01	Ридженерон Фармасьютикалз, Инк.	Способ лечения кожной инфекции путем введения антагониста il-4r
EP3218412A1 (en)	2014-11-14	2017-09-20	Sanofi Biotechnology	Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
ES2764840T3 (es)	2015-01-28	2020-06-04	Univ Bordeaux	Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
JP6947372B2 (ja) *	2015-05-26	2021-10-13	学校法人東京薬科大学	炎症性腸疾患を抑制する抗体および該抗体を含む医薬組成物
EP4442323A3 (en)	2016-09-01	2025-01-01	Regeneron Pharmaceuticals, Inc.	Methods for preventing or treating allergy by administering an il-4r antagonist
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
MA46269B1 (fr)	2017-08-18	2024-05-31	Regeneron Pharma	Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
HUE064655T2 (hu)	2017-10-30	2024-04-28	Sanofi Biotechnology	IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
CN112153982A (zh)	2018-05-13	2020-12-29	瑞泽恩制药公司	用于通过施用il-4r抑制剂治疗特应性皮炎的方法
EP3864042A1 (en) *	2018-10-11	2021-08-18	Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.	Means and methods for detecting soy allergens
MX2021011141A (es)	2019-03-21	2022-01-19	Regeneron Pharma	Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia.
MX2021012163A (es)	2019-04-17	2022-01-31	Univ Hiroshima	Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion.
MX2022000649A (es)	2019-07-16	2022-06-08	Sanofi Biotechnology	Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r.
EP4010001A1 (en)	2019-08-05	2022-06-15	Regeneron Pharmaceuticals, Inc.	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
AU2020326713A1 (en)	2019-08-05	2022-02-17	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0154316B1 (en)	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemically modified lymphokine and production thereof
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
EP0832981A1 (en)	1987-02-17	1998-04-01	Pharming B.V.	DNA sequences to target proteins to the mammary gland for efficient secretion
EP0401384B1 (en)	1988-12-22	1996-03-13	Kirin-Amgen, Inc.	Chemically modified granulocyte colony stimulating factor
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5510264A (en)	1993-09-28	1996-04-23	Insight Biotech Inc.	Antibodies which bind meningitis related homologous antigenic sequences
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
GB9424449D0 (en)	1994-12-02	1995-01-18	Wellcome Found	Antibodies
JPH0967399A (ja)	1995-08-30	1997-03-11	Mitsui Toatsu Chem Inc	抗ｍｃｐ−１ヒトモノクローナル抗体
SE9600820D0 (sv) *	1996-03-01	1996-03-01	Pharmacia Ab	Antibodies and their use
US6312689B1 (en)	1998-07-23	2001-11-06	Millennium Pharmaceuticals, Inc.	Anti-CCR2 antibodies and methods of use therefor
ES2293973T3 (es)	2000-02-03	2008-04-01	Millennium Pharm Inc	Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
AU2001261743C9 (en)	2000-05-19	2006-07-06	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods for reducing tumor growth and metastasis by inhibiting MCP-1 activity
AU2001258836A1 (en)	2000-05-26	2001-12-03	Kensuke Egashira	Preventives and remedies for pulmonary hypertension
GB0016138D0 (en)	2000-06-30	2000-08-23	Novartis Ag	Organic compounds
EP1461300B1 (en)	2001-11-30	2011-07-27	Biogen Idec MA Inc.	Antibodies against monocyte chemotactic proteins
CA2507080C (en)	2002-11-27	2015-01-06	Biogen Idec Ma Inc.	Humanized antibodies against monocyte chemotactic proteins
IT1395574B1 (it)	2009-09-14	2012-10-16	Guala Dispensing Spa	Dispositivo di erogazione

2002
- 2002-11-27 EP EP02792310A patent/EP1461300B1/en not_active Expired - Lifetime
- 2002-11-27 EP EP10180666.9A patent/EP2298717B1/en not_active Expired - Lifetime
- 2002-11-27 EP EP15185855.2A patent/EP2990394A1/en not_active Withdrawn
- 2002-11-27 AR ARP020104579A patent/AR037456A1/es not_active Application Discontinuation
- 2002-11-27 CA CA2468733A patent/CA2468733C/en not_active Expired - Lifetime
- 2002-11-27 DK DK02792310.1T patent/DK1461300T3/da active
- 2002-11-27 WO PCT/US2002/038229 patent/WO2003048083A2/en not_active Ceased
- 2002-11-27 AU AU2002357770A patent/AU2002357770B2/en not_active Expired
- 2002-11-27 AT AT02792310T patent/ATE517855T1/de not_active IP Right Cessation
2004
- 2004-05-27 US US10/855,013 patent/US7405277B2/en not_active Expired - Lifetime
2008
- 2008-07-11 US US12/171,791 patent/US7632501B2/en not_active Expired - Lifetime
2009
- 2009-11-04 US US12/612,087 patent/US7972597B2/en not_active Expired - Lifetime
2011
- 2011-06-09 US US13/156,959 patent/US8431125B2/en not_active Expired - Lifetime
2013
- 2013-04-16 US US13/863,574 patent/US9096665B2/en not_active Expired - Lifetime
2015
- 2015-06-22 US US14/746,555 patent/US20160185846A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1461300A4 (en)	2005-12-28
US8431125B2 (en)	2013-04-30
HK1155720A1 (en)	2012-05-25
AU2002357770B2 (en)	2008-07-31
US20160185846A1 (en)	2016-06-30
US20100166757A1 (en)	2010-07-01
EP1461300A2 (en)	2004-09-29
US7972597B2 (en)	2011-07-05
AU2002357770A1 (en)	2003-06-17
ATE517855T1 (de)	2011-08-15
US20050025768A1 (en)	2005-02-03
US20090017028A1 (en)	2009-01-15
EP1461300B1 (en)	2011-07-27
US9096665B2 (en)	2015-08-04
US20120039873A1 (en)	2012-02-16
CA2468733A1 (en)	2003-06-12
US7632501B2 (en)	2009-12-15
US20140178382A1 (en)	2014-06-26
EP2298717A1 (en)	2011-03-23
EP2990394A1 (en)	2016-03-02
WO2003048083A3 (en)	2004-01-15
CA2468733C (en)	2013-06-11
AR037456A1 (es)	2004-11-10
US7405277B2 (en)	2008-07-29
WO2003048083A2 (en)	2003-06-12
EP2298717B1 (en)	2015-10-28

Publication	Publication Date	Title
DK1461300T3 (da)	2011-10-24	Antistoffer mod kemotaktiske monocytproteiner
DK1409016T3 (da)	2010-06-21	Antistoffer mod OPGL
DK1476185T3 (da)	2013-10-14	Antistoffer mod CD40
EE200300509A (et)	2004-08-16	Antikehad VLA-1 vastu
EP1396500A4 (en)	2005-02-02	ANTI-TRAIL-R ANTIBODIES
DK1313769T3 (da)	2008-09-15	Antistoffer mod humant IL-1beta
NO20044347L (no)	2004-12-13	Anti-alfavbeta6-antistoff
DE602004022855D1 (de)	2009-10-08	Interleukin-10-antikörper
EP1499352A4 (en)	2006-10-11	ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
DE60222658D1 (de)	2007-11-08	Monoklonaler anti-cd-40-antikörper
CY2012003I2 (el)	2020-05-29	Αντισωματα που συνδεονται ανοσοειδικως προς blys
DK1543038T4 (da)	2020-11-09	Proteinoprensning
NO20023677D0 (no)	2002-08-02	Sementeringsmanifold-enhet
NO20023266D0 (no)	2002-07-05	Antistoffer mot humant IL-1
DE60226368D1 (de)	2008-06-19	Stirlingmaschine
DK1689775T3 (da)	2011-09-26	GAG-bindende proteiner
EE200300569A (et)	2004-04-15	CD44v6-spetsiifilised antikehad
DE60105696D1 (de)	2004-10-28	Eisenhaltige Proteinzusammensetzung
EP1359932A4 (en)	2004-06-30	TIP39 POLYPEPTIDES
DE60134224D1 (de)	2008-07-10	Ansaugkrümmer
DE50110795D1 (de)	2006-10-05	Torpedosonar mit mehreren Wandlern
DE60201466D1 (de)	2004-11-11	Einlasskrümmer
FI20011055L (fi)	2002-11-19	Heveiiniä sitovat monoklonaaliset vasta-aineet
EE200300377A (et)	2003-10-15	Loomulikud HI-viiruse vastased antikehad
ITPD20000192A0 (it)	2000-07-28	Anticorpi policlonali